Examines the relation of obesity to endometrial cancer and to ovarian cancer while providing insight into public understanding of the importance of obesity as a risk factor for gynecologic malignancies
Describes major aspects of biology relating obesity to gynecologic cancer including hormonal status, adipokines, adipose stromal cells and in particular, use of model systems to study the impact of obesity in gynecologic malignancies
Discusses the multiple prevention strategies including hormone and lifestyle interventions, extending even to bariatric surgery, along with detailed effects of the impact of obesity on treatment strategies and approach to unique outcomes

Autorentext

Nathan A. Berger, MD, Distinguished University Professor and Hanna-Payne Professor of Experimental Medicine, Biochemistry, Genetics and Oncology, is Director of the Case Western Reserve University Center for Science, Health and Society. He obtained the MD degree from Hahnemann University, Philadelphia, PA, interned at Michael Reese Medical Center, Chicago, IL, and served as a medical resident and Hematology/Oncology Fellow at Washington University, St. Louis, MO. Dr. Berger was a research associate in the Laboratory of Molecular Biology, Gerontology Research Center, NICHD, NIH, Baltimore, MD. He was on the faculty at Washington University School of Medicine, before moving to Case Western Reserve University School of Medicine where he served consecutively as Chief, Hematology/Oncology Division, Cancer Center Director, Dean, CWRU School of Medicine and now Director, Center for Science, Health and Society. His research focuses on model systems to study impact of diet, obesity and exercise on aging and cancer and studies to translate and evaluate these observations in human subjects

Karen H. Lu, MD, is Professor in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX, where she holds the J. Taylor Wharton Distinguished Chair in Gynecologic Oncology. Her main clinical interests include the surgical and medical treatment of women with ovarian and endometrial cancers, as well as the management of women at genetically high risk for these cancer. Dr. Lu completed her undergraduate training at Harvard University and received her MD degree from Yale University School of Medicine. She completed her Obstetrics and Gynecology training at The Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School. She serves as Co-Director for the MD Anderson Clinical Cancer Genetics Program and Director of the High Risk Ovarian Cancer Screening Clinic. She is a national leader in the cancer genetics field and has published seminal articles on hereditary gynecologic cancers. In addition, she serves as Director of the Uterine Cancer Research Program (UCRP) and Principal Investigator of the NCI-sponsored Uterine Cancer Specialized Program of Research Excellence (SPORE). She leads a research team that aims to apply laboratory-based findings to improve the care of gynecologic cancer patients. She serves on the American Society of Clinical Oncology (ASCO) Cancer Prevention Committee, the NCI PDQ Editorial Board for Cancer Genetics and the American College of Obstetricians and Gynecologists (ACOG) Committee on Gynecological Practice Bulletins.

Ann H. Klopp, MD, PhD, is an Associate Professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, Houston, TX. She is a physician-scientist specializing in the treatment of gynecologic cancers with laboratory research focus on energy balance and gynecologic malignancies. Clinically, she is interested in the management of high-risk endometrial and cervical cancers and the use of advanced radiation techniques to minimize toxicity. She leads the Global Oncology program in the Division of Radiation Oncology. She has extensive experience with clinical trials, serving as the PI on a phase III randomized study through the NRG as well as multiple investigator initiated single arm prospective studies at MD Anderson. She is a member of the Corpus steering committee at NRG and the Uterine Task Force of the Gynecologic Cancer Steering Committee at NIH. Her current laboratory research on the impact of obesity and the microenvironment on gynecologic cancers using clinical specimens and murine models is funded by CPRIT, the American Cancer Society and the HPV moonshot program at MD Anderson Cancer Center.

Inhalt

1. Epidemiologic Evidence for the Obesity-Endometrial Cancer Relationship.- 2. Epidemiologic Relationship Between Obesity and Ovarian Cancer.- 3. Public Knowledge of Obesity and Gynecologic Cancer Risk.- 4. Role of Estrogen and Progesterone in Obesity Associated Gynecologic Cancers.- 5. Obesity and Endometrial Cancer Precursors.- 6. Obesity, Adipokines, and Gynecologic Cancer.- 7. Adipose Derived Stromal Cells in Gynecologic Cancers.- 8. Obesity and Endometrial Cancer: Mouse Models for Preclinical Prevention Studies.- 9. Lifestyle Interventions to Reduce the Risk of Obesity-Associated Gynecologic Malignancies: A Focus on Endometrial Cancer.- 10. Hormonal and Metabolic Strategies to Overcome Insulin Resistance and Prevent Endometrial Cancer.- 11. Management of Endometrial Cancer Precursors in Obese Women.- 12. Exercise and Lifestyle Interventions in Gynecologic Cancer Survivors.- 13. Physical Activity as a Risk Factor for Ovarian Cancer.- 14. Impact of Obesity on Surgical Approaches to Gynecologic Malignancies.- 15. Obesity, Fertility Preservation and Gynecologic Cancers.- 16. Metformin as Adjuvant Therapy in Ovarian and Endometrial Cancers.